ROIVANT SCIENCES LTD

Roivant Sciences to report Q4 earnings: robust 100%+ revenue growth but modest EPS decline expected, highlighting a widening gap between top‑line expansion and profitability.

Roivant Sciences’ 9 Nov 2026 update: rising revenue amid projected losses, with breakthrough clinical milestones driving new partnership income and future growth prospects.

Phase‑3 CLARITY shows brepocitinib achieves steroid‑free quiescence in non‑infectious uveitis, with significant visual‑function gains and a safe profile—potentially a new, cost‑effective treatment option.

Roivant Sciences teams up with Akari Therapeutics to license its splice‑modulating ADC platform, aiming for breakthrough oncology treatments amid regulatory and market challenges.

Discover how Roivant Sciences’ recent insider trades and 5‑year gains highlight investor confidence and biotech growth potential.